nach oben

Digestive Diseases and Sciences

Erschienen in:

01.03.2007 | Original ARTICLE

The Multiple Faces of Glucagon-Like Peptide-1—Obesity, Appetite, and Stress: What Is Next? A Review

verfasst von: Eldo E. Frezza, MD, MBA, FACS, Mitchell S. Wachtel, MD, Maurizio Chiriva-Internati, Phd

Erschienen in: Digestive Diseases and Sciences | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Abstract

By itself, glucagon-like peptide-1(GLP-1) appears to be an excellent drug for appetite control and the treatment of obesity. Unfortunately, few enzymes, such as IV dipeptidyl peptidase and renal excretin, degrade and render GLP-1 inactive within minutes. A receptor agonist, exendin-4, with a longer biological half-life than GLP-1, has been tried. Subcutaneous injection of exendin-4 or continuous IV injection of GLP-1 warrants further research and investigation.

Perry T, Lahiri DK, Chen D, et al. (2002) A novel neurotrophic property of glucagon-like peptide-1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 300:958–966PubMedCrossRef

Fehmann HC, Göke R, Göke B (1995) Cell and molecular biology of the incretin hormones glucagon-like peptide 1 and glucose-dependent insulin releasing polypeptide. Endocr Rev 16:390–410PubMedCrossRef

Naslund E, Hellstrom PM (1998). Glucagon-like peptide-1 in the pathogenesis of obesity. Drug News Perspect 11:92–97PubMedCrossRef

Gutzwiller JP, Tschopp S, Bock A, et al. (2004) Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrin Metab 89:3055–3061CrossRef

Eissele R, Goke R, Willemer S, et al. (1992) Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 22:283–291PubMedCrossRef

Jin SL, Han VK, Simmons JG, et al. (1988) Distribution of glucagon-like peptide-1 (GLP-1), glucagon, and glicentin in the rat brain: an immunocytochemical study. J Comp Neurol 271:519–532PubMedCrossRef

Merchenthaler I, Lane M, Shughrue P (1999) Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 403:261–280PubMedCrossRef

Rouille Y, Martin S, Steiner DF (1995) Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide. J Biol Chem 270:26488–26496PubMedCrossRef

Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF (1992) Insulinotropic action of glucagon-like peptide-1-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15:270–276PubMed

10.

Holst JJ (1997) Enteroglucagon. Annu Rev Physiol 59:257–271PubMedCrossRef

11.

Kreymann B, Williams G, Ghatei MA, et al. (1987) Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2:1300–1304PubMedCrossRef

12.

Yoshimoto S, Hirota M, Ohboshi C, et al. (1989) Identification of glucagon-like peptide-1 (7-36) amide in rat brain. Ann Clin Biochem 26:169–171PubMed

13.

Ørskov C, Rabenhøj L, Wettergren A, et al. (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43:535–539PubMed

14.

Mojsov S, Kopczynski MG, Habener JF (1990) Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. J Biol Chem 265:8001–8008PubMed

15.

Kreymann B, Ghatei MA, Burnet P, et al. (1989) Characterization of glucagon-like peptide 1-(7-36)amide in the hypothalamus. Brain Res 502:325–331PubMedCrossRef

16.

Ritzel R, Ørskov C, Holst JJ, et al. (1995) Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose–response-relationships. Diabetologia 38:720–725PubMed

17.

Creutzfeldt WO, Kleine N, Willms B, et al. (1996) Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I [7-36 amide] in type I diabetic patients. Diabetes Care 19:580–586PubMed

18.

Näslund E, Bogefors J, Skogar S, et al. (1999) GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 277:R910–916PubMed

19.

Flint A, Raben A, Ersboll AK, et al. (2001) The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 25:781–792PubMedCrossRef

20.

Meier S, Hucking K, Titzel R, et al. (2003) Absence of a memory effect for the insulinotropic action of glucagon-like peptide-1 (GLP-1) in healthy volunteers. Horm Met Res 35:551–556CrossRef

21.

Silvestre RA, Rodriguez-Gallardo J, Egido EM, et al. (2003) Interrelationship among insulin, glucagon and somatostatin secretory responses to exendin-4 in the perfused rat pancreas. Eur J Pharmacol 469:195–200PubMedCrossRef

22.

Ling Z, Wu D, Zambre Y, et al. (2001) Glucagon-like peptide-1 receptor signalling influences topography of islet cells in mice. Virchows Archiv 438:382–387PubMedCrossRef

23.

Nagai K, Tsuchiya K, Ezaki T, et al. (2004) Effect of GLP-1 (glucagon-like peptide-1:7-36 amide) on porcine pancreatic endocrine cell proliferation and insulin secretion. Pancreas 28:138–145PubMedCrossRef

24.

Meier JJ, Gallwitz B, Schmidt WE, Nauck MA (2002) Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol 440:269–279PubMedCrossRef

25.

Kieffer TJ, McIntosh CH, Pederson RA (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585–3596PubMedCrossRef

26.

Gutzwiller JP, Goke B, Drewe J, et al. (1999) Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 44:81–86PubMedCrossRef

27.

Gutzwiller JP, Drewe J, Goke B, et al. (1999) Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 276:R1541–1544PubMed

28.

Toft-Nielsen MB, Madsbad S, Holst JJ (1999) Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22:1137–1143PubMed

29.

Verdich C, Toubro S, Buemann B, et al. (2001) The role of postprandial releases of insulin and incretin hormones in meal-induced satiety—effect of obesity and weight reduction. Int J Obes Relat Metab Disord 25:1206–1214PubMedCrossRef

30.

Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A (2001) The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 25:781–792PubMedCrossRef

31.

Kalra SP, Dube MG, Pu MG, et al. (1999) Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocrine Rev 20:68–100CrossRef

32.

Schwartz MW, Baskin DG, Kaiyala KJ, et al. (1999) Model for the regulation of energy balance and adiposity by the central nervous system. Am J Clin Nutr 69:584–596PubMed

33.

Meeran K, O’Shea D, Edwards CM, et al. (1999) Repeated intracerebroventricular administration of glucagon-like peptide-1-(7–36) amide or exendin-(9–39) alters body weight in the rat. Endocrinology 140:244–250PubMedCrossRef

34.

Larsen PJ, Tang-Christensen M, Jessop DS (1997) Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 138:4445–4455PubMedCrossRef

35.

Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M, et al. (2004) Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145:2687–2695PubMedCrossRef

36.

Shughrue PJ, Lane MV, Merchenthaler I (1996) Glucagon-like peptide-1 receptor (GLP-1-R) mRNA in the rat hypothalamus. Endocrinology 137:5159–5162PubMedCrossRef

37.

Dakin CL, Small CJ, Park AJ, et al. (2002) Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. Am J Physiol 283:E1173–1177

38.

Dakin CL, Gunn I, Small CJ, et al. (2001) Oxyntomodulin inhibits food intake in the rat. Endocrinology 142:4244–4250PubMedCrossRef

39.

Dakin CL, Small CJ, Park AJ, et al. (2002) Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. Am J Physiol 283:E1173–1177

40.

Tang-Christensen M, Vrang N, Larsen PJ (2001) Glucagon-like peptide containing pathways in the regulation of feeding behaviour. Int J Obes Relat Metab Disord 25[Suppl 5]:S42–47PubMedCrossRef

41.

Fehmann HC, Jiang J, Schweinfurth J, et al. (1994) Stable expression of the rat GLP-I receptor in CHO cells: activation and binding characteristics utilizing GLP-I (7–36) -amide, oxyntomodulin, exendin-4, and exendin (9–39). Peptides 15:453–456PubMedCrossRef

42.

Dakin CL, Small CJ, Batterham RL, et al. (2004) Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145:2687–2695PubMedCrossRef

43.

Yamamoto H, Kishi T, Lee CE, et al. (2003) Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci 23:2939–2946PubMed

44.

Cohen MA, Ellis SM, Le Roux CW, et al. (2003) Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 88:4696–701PubMedCrossRef

45.

Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR (1985) Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89:1070–1077PubMed

46.

Sarkar S, Fekete C, Legradi G, et al. (2003) Glucagon-like peptide-1 (7-36) amide (GLP-1) nerve terminals densely innervate corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Brain Res 985:163–168PubMedCrossRef

47.

Alvarez E, Roncero I, Chowen JA, et al. (1996) Expression of the glucagon-like peptide-1 receptor gene in rat brain. J Neurochem 66:920–997PubMedCrossRef

48.

Møller C, Sommer W, Thorsell A, et al. (2002) Anxiogenic-like action of centrally administered glucagon-like peptide-1 in a punished drinking test. Prog Neuropsychopharmacol Biol Psychiatry 26:119–122PubMedCrossRef

49.

Kinzig KP, D’Alessio DA, Herman JP, et al. (2003) CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors. J Neurosci 23:6163–6170PubMed

50.

Malendowicz LK, Nussdorfer GG, Nowak KW, et al. (2003) Exendin-4, a GLP-1 receptor agonist, stimulates pituitary-adrenocortical axis in the rat: investigations into the mechanism(s) underlying Ex4 effect. Int J Mol Med 12:237–241PubMed

51.

Rinaman L (1999) Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus. Am J Physiol 277:R582–590PubMed

52.

MacLusky NJ, Cook S, Scrocchi L, et al. (2000) Neuroendocrine function and response to stress in mice with complete disruption of glucagon-like peptide-1 receptor signaling. Endocrinology 141:752–762PubMedCrossRef

53.

Andreis PG, Malendowicz LK, Neri G, et al. (1999) Effects of glucagon and glucagon-like peptide-1 on glucocorticoid secretion of dispersed rat adrenocortical cells. Life Sci 64:2187–2197PubMedCrossRef

54.

Peters CT, Choi YH, Brubaker PL, et al. (2001) A glucagon-like peptide-1 receptor agonist and an antagonist modify macronutient selection by rats. J Nutr 131:2164–2170PubMed

55.

Iritani N, Sugimoto T, Fukuda H, Komiya M, Ikeda H (1999) Oral triacylglycerols regulate plasma glucagon-like peptide-1(7-36) and insulin levels in normal and especially in obese rats. J Nutrition 129:46–50

56.

Vilsboll T, Krarup T, Sonne J, et al. (2003) Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 88:2706–2713PubMedCrossRef

57.

Vilsboll T, Agerso H, Krarup T, et al. (2003) Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88:220–224PubMedCrossRef

58.

Velasquez-Mieyer PA, Cowan PA, Umpierrez GE, et al. (2003) Racial differences in glucagon-like peptide-1 (GLP-1) concentrations and insulin dynamics during oral glucose tolerance test in obese subjects. Int J Obes Relat Metab Disord 27:1359–1364PubMedCrossRef

59.

Feinle C, Chapman IM, Wishart J, et al. (2002) Plasma glucagon-like peptide-1 (GLP-1) responses to duodenal fat and glucose infusions in lean and obese men. Peptides 23:1491–1495PubMedCrossRef

60.

Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V (1996) Attenuated GLP-1 secretion in obesity: cause or consequence? Gut 38:916PubMed

61.

Tomasik PJ, Sztefko K, Malek A (2002) GLP-1 as a satiety factor in children with eating disorders. Horm Metab Res 34:77–80PubMed

62.

Lugari R, Dei Cas A, Ugolotti D, et al. (2004) Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion. Horm Metab Res 36:111–115PubMedCrossRef

63.

Fukase N, Igarashi M, Takahashi H, et al. (1993) Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients. Diabet Med 10:44–49PubMed

64.

Feinle C, Chapman IM, Wishart J, et al. (2002) Plasma glucagon-like peptide-1 (GLP-1) responses to duodenal fat and glucose infusions in lean and obese men. Peptides 23:1491–1495PubMedCrossRef

65.

66.

67.

Navarro M, Rodriguez de Fonseca F, Alvarez E, et al. (1996) Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transported GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J Neurochem 67:1982–1991PubMedCrossRef

68.

Meier JJ, Gallwitz B, Schmidt WE, et al. (2002) Glucagon-like peptide-1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol 440:269–279PubMedCrossRef

69.

Larsen PJ, Vrang N, Tang-Christensen M (2003) Central pre-proglucagon derived peptides: opportunities for treatment obesity. Curr Pharm Des 9:1373–1382.PubMedCrossRef

70.

Young AA, Gedulin BR, Bhavsar S, et al. (1999) Glucose-lowering and insulin-sensitizing actions of Exendin-4: Studies in obese diabetic (ob(ob, db(db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48:1026–1034PubMed

71.

Szayna M, Doyle ME, Betkey JA, et al. (2000) Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141:1936–1941PubMedCrossRef

72.

Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M (2001) Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 50:2530–2539PubMed

73.

Naslund E (2004) Prandial subcutaneous injections of GLP-1 cause weight loss in obese human subjects. Br J Nutr 91:439–446PubMedCrossRef

74.

Grandt D, Schimiczek M, Beglinger C, Layer P, Goebell H, Eysselein VE, et al. (1994) Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul Pept 51:151–159PubMedCrossRef

75.

Batterham RL, Cowley MA, Small CJ, et al. (2002) Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418:650–654PubMedCrossRef

76.

Halatchev IG, Ellacott KL, Fan W, et al. (2004) Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. Endocrinology 145:2585–2590PubMedCrossRef

77.

Kojima M, Hosoda H, Date Y, et al. (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656–660PubMedCrossRef

78.

Guan XM, Yu H, Palyha OC, McKee KK, Feighner SD, Sirinathsinghji DJ, et al. (1997) Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Brain Res Mol Brain Res 48:23–29PubMedCrossRef

79.

Katayama M, Nogami H, Nishiyama J, Kawase T, Kawamura K (2000) Developmentally and regionally regulated expression of growth hormone secretagogue receptor mRNA in rat brain and pituitary gland. Neuroendocrinology 72:333–340PubMedCrossRef

80.

Shintani M, Ogawa Y, Ebihara K, et al. (2001) Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y(Y1 receptor pathway. 50:227–232

81.

Clark JT, Kalra PS, Kalra SP (1985) Neuropeptide Y stimulates feeding but inhibits sexual behavior in rats. Endocrinology 117:2435–2442PubMedCrossRef

82.

Cummings DE, Purnell JQ, Frayo RS, et al. (2001) A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50:1714–1719PubMed

83.

Wren AM, Seal LJ, Cohen MA, et al. (2001) Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86:5992PubMedCrossRef

84.

Nakazato M, Murakami N, Date Y, et al. (2001) A role for ghrelin in the central regulation of feeding. Nature 409:194–198PubMedCrossRef

85.

Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S, et al. (2000) The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 141:4325–4328PubMedCrossRef

86.

Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, Cohen MA, et al. (2001) Ghrelin causes hyperphagia and obesity in rats. Diabetes 50:2540–2547PubMed

87.

Laferrere B, Abraham C, Russell CD, et al. (2005) Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab 90:611–614PubMedCrossRef

88.

Frezza EE (2004) Are we closer in finding the treatment for type ii diabetes mellitus in morbid obesity—are the incretins the key to success? Obesity Surgery 14:999–1005PubMedCrossRef

89.

Cummings DE, Shannon MH (2003) Ghrelin and gastric bypass: is there a hormonal contribution to surgical weight loss? J Clin Endocrinol Metab 88:2999–3002PubMedCrossRef

90.

Rubino F, Gagner M, Gentileschi P, Kini S, Fukuyama S, Feng J, et al. (2004) The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 240:236–242PubMedCrossRef

91.

Naslund E, Gryback P, Hellstrom PM, Jacobsson H, Holst JJ, Theodorsson E, et al. (1997) Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int J Obes Relat Metab Disord 21:387–392PubMedCrossRef

Titel: The Multiple Faces of Glucagon-Like Peptide-1—Obesity, Appetite, and Stress: What Is Next? A Review
verfasst von: Eldo E. Frezza, MD, MBA, FACS
Mitchell S. Wachtel, MD
Maurizio Chiriva-Internati, Phd
Publikationsdatum: 01.03.2007
Verlag: Kluwer Academic Publishers-Plenum Publishers
Erschienen in: Digestive Diseases and Sciences / Ausgabe 3/2007
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-006-9096-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2007

The Influence of Gallbladder Function on the Symptomatology in Gallstone Patients, and the Outcome after Cholecystectomy or Expectancy

Octreotide/Midodrine Therapy Significantly Improves Renal Function and 30-Day Survival in Patients with Type 1 Hepatorenal Syndrome

Age-Related Variation of Intraepithelial Lymphocytes Subsets in Normal Human Duodenal Mucosa

Dermatitis Herpetiformis: No Evidence of Bone Disease Despite Evidence of Enteropathy

High Proportions of Proinflammatory Bacteria on the Colonic Mucosa in a Young Patient with Ulcerative Colitis as Revealed by Cloning and Sequencing of 16S rRNA Genes